Abstract. Diabetes mellitus is the 4 main reason of death in the whole world. There are 382 million of people, suffering from diabetes in the world, in Ukraine 1,04 million. 90 % of all cases is type 2 diabetes. Obesity is the main risk of development of type 2 diabetes. 600 million people in the world suffer from obesity, 9 million – in Ukraine. Diabetes mellitus and obesity are the main risk factors of arterial hypertension, stroke, coronary artery disease, heart failure and chronic kidney disease. Diabetic nephropathy in most cases leads to the end stage of renal disease and recquires dialysis. Obesity in patients with comorbidities plays a huge role in disease progression. Obesity leads to chronic inflammation, what results in insulin resistance, metabolic syndrome and type 2 diabetes. Obesity with type 2 diabetes leads to hyperfiltration, albuminuria, activation of angiotensin-aldosteron system and release of proinflammatory cytokines. Incidence of type 2 diabetes is growing every year. Vascular complications of diabetes are dangerous and in the most cases lead to death. Among them chronic kidney disease takes special place. Kidney impairment in patients with type 2 diabetes is asymptomatic on the early stages, but it quickly develops to the end stage of renal disease. That’s why it is important to diagnose it on the early stages. Type 2 diabetes is related to inflammation, oxidative stress and endothelial dysfunction. But it remains unknown if these processes lead to kidney damage in such patients, what plays a key role in disease progression. Malondialdehyde is a marker of oxidative stress and its accumulation leads to endothelium damage. Oxide dismutase is an antioxidant ferment and it protects human body from toxic radicals. The aim of the study is to investigate if there is any connection between oxidative stress indicators and markers of chronic kidney disease. The investigation included 80 patients with type 2 diabetes. Except standard laboratory and physical examinations, additional blood sample has been taken for malondialdehyde and oxide dismutase detection; also nitrogen oxide and its metabolites have been measured. All patients have been divided into 2 groups: without and with chronic kidney disease. The results of the study showed that in patients with chronic kidney disease level of malondialdehyde has been significantly higher, than in patients without kidney damage. But 1 group has had a level of oxide dismutase much higher. With decrease of glomerular filtration rate level, a level of malondialdehyde also increases. This confirms a role of oxidative stress products in kidney impairment in patients with type 2 diabetes.
Full text: PDF (Ukr) 768K